BioWorld-International-2009-09-16
Alcon Paying Up to $589M for EsbaTech Eye Business
Alcon Paying Up to $589M for EsbaTech Eye Business
Underlining the current vogue for antibody-based technologies, Alcon Inc. is acquiring the ophthalmology business of ESBATech AG for $150 million in cash plus up to $439 million in potential milestones. (BioWorld International)

